785-827-4455
Salina's only locally owned pharmacy since 1953

For Physicians.

 

Meniett® Therapy for Physicians

An increasing number of physicians are looking for minimally invasive alternatives to painful surgery or gentamicin injections for treatment of Ménière’s disease. The Meniett® micropressure therapy generator is non-evasive, effective, and supported by years of clinical research.

AAO-HNS’ Position Statement on micropressure therapy (updated in March 2016) states: “Micropressure therapy can be used as a second level therapy when medical treatment has failed”. 

Meniett® therapy for Ménière’s disease is Medicare covered when proven medically necessary. The Meniett® generator is considered Durable Medical Equipment (DME) and is covered nationally by Medicare through the Durable Medical Equipment Regional Carriers (DMERC) when proven medically necessary.

Meniere's Treatment Levels 

 

 Meniett® Treatment

Managing Ménière’s disease can be a significant clinical challenge as each Ménière’s disease patient progresses and responds differently. For physician’s, managing Ménière’s disease symptoms at an acceptable level with the most conservative and non-evasive treatment method is the goal.

Micropressure therapy is a simple, effective, and non-evasive treatment for the vertigo symptoms of Ménière’s disease.

Clinical references

Micro-pressure therapy with the Meniett® generator is based on nearly 30 years of research both in the U.S. and Internationally. Short-term and long-term results have been studied in Meniere’s disease patients, including randomized, double-blinded, placebo-controlled trials.

Research concludes that for the majority of patients Meniett® therapy is a simple and effective treatment for the vertigo symptoms of Meniere’s disease.

Randomized Controlled Trials

  1. Gurkov R, Filipe Mingas LB, Rader T, Louza J, Olzowy B, Krause E. Effect of transtympanic low-pressure therapy in patients with unilateral Meniere’s disease unresponsive to betahistine: A randomised, placebo-controlled, double-blinded, clinical trial. J Laryngol Otol 2012;126:356-362.
  2. Thomsen J, Sass K, Odkvist L, Arlinger S. Local overpressure treatment reduces vestibular symptoms in patients with Meniere’s disease: A clinical, randomized, multicenter,, double-blind, placebo-controlled study. Otology and Neurotology 2005;26:68-73
  3. Gates GA, Green J, Tucci DL, Telian SA. The effects of transtympanic micro pressure treatment in people with unilateral Meniere’s disease. Arch Otolaryngol Head Neck Surg 2004;130:718-725
  4. Odkvist LM, Arlinger S, Billermark E, Densert B, Lindholm S, Wallqvist J. Effects of middle ear pressure changes on clinical symptoms in patients with Meniere’s disease – A clinical multicenter placebo-controlled study. Acta Oto-Laryngol Suppl 2000;99-101
  5. Densert B, Densert O, Arlinger S, Sass K, Odkvist L. Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Meniere’s disease: A clinical placebo-controlled study. AM J OTOL 1997;18:726- 733.Other Clinical References 

Other Clinical References

  1. Barbara M, Monini S, Chiappini I, Filipo R. Meniett therapy may avoid vestibular neurectomy in disabling Meniere’s disease. Acta Oto-Laryngol 2007;127:1136-1141.
  2. Barbara M, Lazzarino AI, Biagini M, Costa M, Monini S. Influence of Meniett treatment on hearing. Acta Oto-Laryngol 2010;130:1256-1259
  3. Densert B, Sass K. Control of symptoms in patients with Meniere’s disease using middle ear pressure applications: Two years follow-up. Acta Oto-Laryngol 2001;121:616-621
  4. Dornhoffer JL, King D. The effect of the Meniett device in patients with Meniere’s disease: Long-term results. Otology and Neurotology 2008;29:868-874
  5. Huang W, Liu F, Gao B, Zhou J. Clinical long-term effects of Meniett pulse generator for Meniere’s disease. Acta Oto-Laryngol 2009;129:819-825.
  6. Mattox DE, Reichert M. Meniett device for Meniere’s disease: Use and compliance at 3 to 5 years. Otology and Neurotology 2008;29:29-32.
  7. Rajan GP, Din S, Atlas MD. Long-term effects of the Meniett device in Meniere’s disease: The Western Australian experience. J Laryngol Otol 2005;119:391-395.
  8. Shojaku H, Watanabe Y, Mineta H et al. Long-term effects of the Meniett device in Japanese patients with Meniere’s disease and delayed endolymphatic hydrops reported by the Middle Ear Pressure Treatment Research Group of Japan. Acta Oto- Laryngol 2011;131:277-283.
  9. Gates GA, Verrall A, Green J, Tucci DL, Telian SA. Meniett clinical trial: Long-term follow-up. Arch Otolaryngol Head Neck Surg 2006;132:1311-1316